Role of iron chelator in oxidative stress

Not Applicable

• Conditions: critically ill mechanically ventilated patients.; Respiratory failure, unspecified

• Registration Number: IRCT138709181497N1
• Lead Sponsor: Pharmaceutical Science Research Center of Pharmacy Faculty of Tehran University Of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Mechanically ventilated patients, Fio2 more than 50% for at least 3 days and PEEP equal to 5, Ability to receive drug by oral route Exclusion criteria: Dissatisfaction of patients or family, other diseases that cause pulmonary edema such as CHF, pulmonary hemorrhage, age less than 18, patients who are NPO, severe liver failure (ALT, AST>5 times of baseline), moderate to severe renal failure (Cr >1mg/dl or u/o <0.5cc/kg/hr or dialysis), patients who are in shock (PH <7.2 , Pao2/Fio2 <100 , MAP< 65), receiving other anti-inflammatory drugs such as NAC or corticosteroids, history of leukemia, BMT, thalassemia, iron deficiency anemia, receiving iron chelator drugs during 3 months prior to the study, receiving chemotherapy or immunosuppressive drugs during 3 months prior to the study, Level of ferritin less than 30 mcg/L, Grade 2-3 of heart block, QT prolongation, positive viral markers such as HIV, HBV , HCV, WBC<3000, ANC<1500, PLT<50000, Ejection Fraction <55%

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
8-isoprostane in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug administration. Method of measurement: human elisa kit.;Carbonyl protein in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug. Method of measurement: human elisa kit.;8-oxoguanin in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug. Method of measurement: human elisa kit.;Ferritin in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug. Method of measurement: human elisa kit.;Transferrin in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug. Method of measurement: human elisa kit.;Free iron in plasma and BAL fluid. Timepoint: 0 and 72 hour after drug. Method of measurement: spectroscopy method.

Secondary Outcome Measures

Name	Time	Method
Mortality rate. Timepoint: from the time of treatment until 1 week. Method of measurement: APACHE2.;Assesment of organ failure. Timepoint: from the time of treatment until 1 week. Method of measurement: SOFA.